Previous 10 | Next 10 |
SOUTH SAN FRANCISCO, Calif., Dec. 02, 2021 (GLOBE NEWSWIRE) -- Lyell Immunopharma, Inc. (Lyell), (Nasdaq: LYEL), a T cell reprogramming company dedicated to the mastery of T cells to cure patients with solid tumors, today announced that Dr. Rick Klausner is resuming his role as Chair of Lye...
Lyell Immunopharma (NASDAQ:LYEL): Q3 Net Loss of $48.87M Revenue of $2.75M (+157.0% Y/Y) beats by $0.45M. Press Release For further details see: Lyell Immunopharma EPS beats by $49.14, beats on revenue
Cash and investments of $936.4 million as of September 30, 2021 supports advancing multi-modality cell therapy pipeline SOUTH SAN FRANCISCO, Calif., Nov. 12, 2021 (GLOBE NEWSWIRE) -- Lyell Immunopharma, Inc. (Lyell), (Nasdaq: LYEL), a T cell reprogramming company dedicated to the ...
Healthcare stocks in the S&P 500 edged past the ~0.6% loss in the broader index over the week to end ~0.2% lower, becoming the fourth best performing sector. Among stocks with more than $300M market cap and over 100K average daily volume over the past five sessions, BELLUS Health (NA...
Gainers: Itamar (NASDAQ:ITMR) +46%. Aterian (NASDAQ:ATER) +40%. aTyr Pharma (NASDAQ:LIFE) +37%. iRhythm Technology (NASDAQ:IRTC) +34%. BELLUS (NASDAQ:BLU) +26%. Leap Therapeutics (NASDAQ:LPTX) +30%. REGENXBIO (NASDAQ:RGNX) +25%. Datasea (NASDAQ:DTSS) +20%. Uranium Royalty (NASDAQ:UROY) ...
Gainers: Itamar Medical ITMR +45%, aTyr Pharma LIFE +35%, iRhythm Technologies (NASDAQ:IRTC) +33%, REGENXBIO RGNX +20%, Leap Therapeutics LPTX +15%. Losers: MiMedx MDXG -61%, Silverback Therapeutics (NASDAQ:SBTX) -24%, Dynavax T...
SOUTH SAN FRANCISCO, Calif., Sept. 08, 2021 (GLOBE NEWSWIRE) -- Lyell Immunopharma, Inc. (Lyell), (Nasdaq: LYEL), a T cell reprogramming company dedicated to the mastery of T cells to cure patients with solid tumors, today announced that members of its senior management team will participat...
Lyell Immunopharma Inc. (NASDAQ:LYEL) traded at a new 52-week high today of $19.75. This new high was reached on approximately average trading volume as 221,000 shares traded hands, while the average 30-day volume is approximately 201,000 shares. Lyell Immunopharma Inc is a T cell reprog...
Achieved operational readiness of state-of-the-art LyFE manufacturing facility to support multiple clinical trials Cash, cash equivalents and marketable securities of $974.8 million as of June 30, 2021 includes $391.8 million in net proceeds from initial public offering SOUTH SA...
Lyell Immunopharma Inc. (NASDAQ:LYEL) traded at a new 52-week low today of $13.82. This new low was reached on below average trading volume as 221,000 shares traded hands, while the average 30-day volume is approximately 595,000 shares. Lyell Immunopharma Inc. share prices have moved bet...
News, Short Squeeze, Breakout and More Instantly...
Lyell Immunopharma Inc. Company Name:
LYEL Stock Symbol:
NASDAQ Market:
Lyell Immunopharma Inc. Website:
A look at the top 10 most actives in the United States Faraday Future Intelligent Electric Inc. (FFIE) rose 73.0% to $0.4585 on volume of 640,087,036 shares Ocean Power Technologies Inc. (OPTT) rose 34.9% to $0.1812 on volume of 396,326,565 shares NVIDIA Corporation (NVDA) rose 0.2% to $1...
A look at the top 10 most actives in the United States Ocean Power Technologies Inc. (OPTT) rose 56.4% to $0.21 on volume of 112,154,340 shares Rivian Automotive Inc. (RIVN) rose 31.8% to $15.76 on volume of 70,797,368 shares Faraday Future Intelligent Electric Inc. (FFIE) rose 48.3% to $...
Dose-dependent antitumor clinical activity in ROR1+ relapsed/refractory triple-negative breast cancer; 40% objective response rate and 60% clinical benefit rate at the highest dose cleared to date (150 x 10 6 CAR T cells) First demonstration that CAR T cells enhanced with anti-exhaus...